HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Jeffrey Schlom Selected Research

Vaccinia

10/2010Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.
5/2010Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
7/2009Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
6/2009Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients.
5/2008Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
10/2007Clinical safety of a viral vector based prostate cancer vaccine strategy.
9/2007The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses.
5/2005Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
2/2005Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
2/2005Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Jeffrey Schlom Research Topics

Disease

111Neoplasms (Cancer)
11/2015 - 01/2002
28Carcinoma (Carcinomatosis)
11/2015 - 05/2002
27Prostatic Neoplasms (Prostate Cancer)
10/2015 - 01/2002
17Vaccinia
10/2010 - 01/2002
13Fowlpox
10/2010 - 10/2002
10Neoplasm Metastasis (Metastasis)
12/2014 - 06/2003
7Adenocarcinoma
10/2015 - 01/2002
3Chordoma
11/2015 - 03/2015
3Breast Neoplasms (Breast Cancer)
11/2015 - 05/2014
3B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
10/2010 - 11/2005
3Infection
06/2009 - 07/2004
2Colorectal Neoplasms (Colorectal Cancer)
11/2015 - 02/2004
2Melanoma (Melanoma, Malignant)
10/2015 - 02/2006
2Mesothelioma
10/2015 - 09/2005
2Hematologic Neoplasms (Hematological Malignancy)
02/2014 - 08/2008
2Lung Neoplasms (Lung Cancer)
07/2012 - 06/2008
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
07/2012 - 03/2006
2Communicable Diseases (Infectious Diseases)
05/2012 - 01/2008
2Disease Progression
01/2007 - 02/2006
2Ovarian Neoplasms (Ovarian Cancer)
09/2005 - 09/2002
1Edema
11/2015
1Embryonal Carcinoma
10/2015
1Seminoma
10/2015
1Small Cell Carcinoma
10/2015
1Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
10/2015
1Sarcoma (Soft Tissue Sarcoma)
10/2015
1Hemangioblastoma
03/2015
1Necrosis
04/2014
1Fever (Fevers)
09/2013
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2013
1Colitis
05/2012
1Exanthema (Rash)
05/2012
1Neutropenia
05/2012
1Urinary Bladder Neoplasms (Bladder Cancer)
08/2009

Drug/Important Bio-Agent (IBA)

56AntigensIBA
10/2015 - 01/2002
37VaccinesIBA
11/2015 - 01/2002
28Carcinoembryonic AntigenIBA
11/2015 - 01/2002
18Prostate-Specific Antigen (Semenogelase)IBA
08/2014 - 01/2002
13Cancer VaccinesIBA
01/2014 - 11/2004
11Brachyury protein (Brachyury)IBA
11/2015 - 04/2007
11Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
10/2010 - 10/2002
9Transcription Factors (Transcription Factor)IBA
11/2015 - 04/2007
9Neoplasm Antigens (Tumor Antigens)IBA
09/2011 - 01/2002
8CD58 Antigens (LFA-3)IBA
10/2010 - 10/2002
6Immunoglobulin G (IgG)IBA
10/2015 - 04/2002
5docetaxel (Taxotere)FDA Link
11/2015 - 02/2006
5HLA-A2 Antigen (HLA A2 Antigen)IBA
12/2014 - 03/2004
5Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
10/2007 - 05/2003
4Interleukin-12 (IL 12)IBA
10/2015 - 08/2009
4Messenger RNA (mRNA)IBA
05/2014 - 01/2002
4AntibodiesIBA
04/2014 - 04/2006
4ipilimumabIBA
04/2014 - 02/2007
4CytokinesIBA
10/2012 - 01/2007
4Interleukin-2 (IL2)IBA
12/2007 - 05/2003
3Monoclonal AntibodiesIBA
10/2015 - 09/2007
3PeptidesIBA
02/2014 - 11/2003
3CD40 Ligand (CD40L)IBA
10/2012 - 07/2004
3ChitosanIBA
09/2010 - 03/2007
3HormonesIBA
07/2008 - 08/2005
3Carbon MonoxideIBA
10/2007 - 01/2002
3lymphotactinIBA
08/2007 - 11/2003
3Glycoproteins (Glycoprotein)IBA
10/2003 - 09/2002
2TamoxifenFDA LinkGeneric
03/2015 - 05/2014
2PerforinIBA
12/2014 - 09/2002
2sipuleucel-T (APC8015)FDA Link
07/2012 - 01/2012
2Complementary DNA (cDNA)IBA
08/2010 - 05/2003
2Fas Ligand Protein (Fas Ligand)IBA
08/2008 - 06/2004
2AutoantigensIBA
01/2006 - 05/2003
2EpitopesIBA
09/2005 - 08/2003
2Deoxycytidine (CDR)IBA
10/2003 - 10/2002
1Immunoglobulin M (IgM)IBA
10/2015
1Bacterial VaccinesIBA
12/2014
1erbB-2 Receptor (Receptor, erbB 2)IBA
01/2014
1trastuzumab (Herceptin)FDA Link
01/2014
1Synthetic Vaccines (Recombinant Vaccines)IBA
10/2013
1talactoferrin alfaIBA
01/2013
1HLA-DR Antigens (HLA-DR)IBA
10/2012
1Phosphotransferases (Kinase)IBA
07/2012
1Epidermal Growth Factor Receptor (EGF Receptor)IBA
07/2012
1Combined VaccinesIBA
06/2012
1TransaminasesIBA
05/2012
1A-Form DNA (A-DNA)IBA
01/2011
1obatoclaxIBA
10/2010
1Proteins (Proteins, Gene)IBA
08/2010
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
03/2010
1Transforming Growth Factor beta (TGF-beta)IBA
11/2009
1nilutamide (Nilandron)FDA Link
07/2008
1Mucin-1 (CA 15-3 Antigen)IBA
07/2008
1TaxoidsIBA
06/2008
1Viral VaccinesIBA
06/2008

Therapy/Procedure

32Immunotherapy
10/2015 - 01/2002
10Drug Therapy (Chemotherapy)
04/2014 - 09/2002
9Castration
04/2014 - 07/2008
6Therapeutics
03/2015 - 01/2007
4Heterologous Transplantation (Xenotransplantation)
02/2010 - 05/2002
4Radioimmunotherapy
04/2006 - 04/2002
3Radiotherapy
08/2010 - 05/2005
2Injections
09/2010 - 04/2004
1Subcutaneous Injections
09/2013
1Biological Therapy
01/2010